Innovative MedTech Startups Join Forces in the I-CREATE Program
MedTech Innovations Thriving at I-CREATE Accelerator
University Lab Partners (ULP) is excited to announce the selection of nine pioneering MedTech companies that will embark on their journey in the inaugural cohort of the International Consortium for Research, Engineering, and Acceleration of Technology Excellence (I-CREATE). This accelerator is designed to be a beacon for nourishing groundbreaking innovations within the healthcare sector.
Welcome to the I-CREATE Accelerator Program
ULP is committed to fostering innovative developments that can significantly impact health security. Sandra J. Miller, Executive Director of University Lab Partners, expressed her enthusiasm, stating, "We are thrilled to welcome this exceptional group of companies, representing diverse and groundbreaking innovations. We look forward to supporting them, alongside our partners, as they advance their technologies to address critical health security challenges. This initiative underscores our mission to empower startups making substantial contributions to public health and safety."
What is I-CREATE?
I-CREATE is a pioneering program among the five strategic hubs of the BARDA Accelerator Network (BAN 2.0). Its focus is on empowering innovative startups that are reshaping the landscape of medical devices and diagnostics globally. The program aims to spur advancements in technology essential for developing countermeasures against public health threats including chemical, biological, radiological, and nuclear (CBRN) threats and emerging infectious diseases.
Funding and Mentorship Opportunities
As part of the accelerator initiative, three companies will be granted up to $200,000 in non-dilutive funding. Additionally, they will benefit from tailored mentorship and consulting over a six-month period, designed specifically to nurture the development, evaluation, or validation of their respective medical or diagnostic solutions.
Meet the Selected Companies
The selected cohort includes a diverse array of innovators showcasing remarkable potentials: Lo Biosciences, Rua Diagnostics, and Adaptyx are among those that will receive significant funding for their proposed projects.
Investment in Future-Ready Solutions
Moreover, six additional companies have been invited to take part in a six-month accelerator program emphasizing personalized workshops, advisory services, and competitive mentorship. These companies will be contending for a prize of up to $50,000, aimed at elevating their projects further within the realm of health technology.
Spotlight on Participating Startups
These promising participants include Acorn Genetics, Checktor Biosciences, VIDEM, Mitos Diagnostics, Hikari Medical Technology, and Latde Diagnostics, collectively bringing fresh ideas to the forefront of healthcare technology.
Showcasing Innovations
On May 20, 2025, all nine companies will showcase their innovations during the I-CREATE Virtual Showcase, connecting them with potential investors who can further support their expansion and development.
This groundbreaking project is brought to fruition through collaboration and support from federal resources dedicated to enhancing the nation’s health security infrastructure. This association with the U.S. Department of Health and Human Services highlights the importance of innovation in combatting persistent health threats.
About I-CREATE and ULP
The I-CREATE program exists to bridge the gap between emerging startups and a network of investors, industry leaders, and experienced mentors. At the same time, University Lab Partners serves as a leading nonprofit wet lab incubator in the region, providing state-of-the-art facilities and nurturing a vibrant entrepreneurial ecosystem focused on life sciences. ULP's efforts support innovators through global accelerator programs, and workforce development initiatives that advance the life sciences ecosystem worldwide.
Frequently Asked Questions
What is the I-CREATE Accelerator?
The I-CREATE Accelerator is a program designed to support innovative startups in the MedTech field by providing funding and mentorship.
How many companies were selected for the program?
Nine pioneering MedTech companies were selected for the inaugural cohort of the I-CREATE Accelerator.
What kind of funding do selected companies receive?
Each selected company can receive up to $200,000 in non-dilutive funding tailored to their specific needs.
What is the goal of the I-CREATE program?
The program aims to accelerate the development and commercialization of medical devices and diagnostics to enhance public health.
When will the companies showcase their innovations?
All participating companies will present their innovations at the I-CREATE Virtual Showcase on May 20, 2025.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
